Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden.

Global survival studies have shown favorable development in renal cell carcinoma (RCC) treatment but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed RCC survival in Finland and Sweden over a 50-year period (1967-20...

Full description

Bibliographic Details
Main Authors: Kari Hemminki, Asta Försti, Akseli Hemminki, Börje Ljungberg, Otto Hemminki
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0253236
_version_ 1818736844873924608
author Kari Hemminki
Asta Försti
Akseli Hemminki
Börje Ljungberg
Otto Hemminki
author_facet Kari Hemminki
Asta Försti
Akseli Hemminki
Börje Ljungberg
Otto Hemminki
author_sort Kari Hemminki
collection DOAJ
description Global survival studies have shown favorable development in renal cell carcinoma (RCC) treatment but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed RCC survival in Finland and Sweden over a 50-year period (1967-2016) using data from the NORDCAN database provided by the local cancer registries. While the health care systems are largely similar in the two countries, the economic resources have been stronger in Sweden. In addition to the standard 1- and 5-year relative survival rates, we calculated the difference between these as a measure of how well survival was maintained between years 1 and 5. Relative 1- year survival rates increased almost linearly in both countries and reached 90% in Sweden and 80% in Finland. Although 5-year survival also developed favorably the difference between 1- and 5-year survival rates did not improve in Sweden suggesting that the gains in 5-year survival were entirely due to gains in 1-year survival. In Finland there was a gain in survival between years 1 and 5, but the gain in 1-years survival was the main contributor to the favorable 5-year survival. Age group specific analysis showed large survival differences, particularly among women. Towards the end of the follow-up period the differences narrowed but the disadvantage of the old patients remained in 5-year survival. The limitations of the study were lack of information on performed treatment and clinical stage in the NORDCAN database. In conclusion, the available data suggest that earlier diagnosis and surgical treatment of RCC have been the main driver of the favorable change in survival during the past 50 years. The main challenges are to reduce the age-specific survival gaps, particularly among women, and push survival gains past year 1.
first_indexed 2024-12-18T00:43:37Z
format Article
id doaj.art-087cc32668694de4896935b1599092b9
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-18T00:43:37Z
publishDate 2021-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-087cc32668694de4896935b1599092b92022-12-21T21:26:49ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01166e025323610.1371/journal.pone.0253236Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden.Kari HemminkiAsta FörstiAkseli HemminkiBörje LjungbergOtto HemminkiGlobal survival studies have shown favorable development in renal cell carcinoma (RCC) treatment but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed RCC survival in Finland and Sweden over a 50-year period (1967-2016) using data from the NORDCAN database provided by the local cancer registries. While the health care systems are largely similar in the two countries, the economic resources have been stronger in Sweden. In addition to the standard 1- and 5-year relative survival rates, we calculated the difference between these as a measure of how well survival was maintained between years 1 and 5. Relative 1- year survival rates increased almost linearly in both countries and reached 90% in Sweden and 80% in Finland. Although 5-year survival also developed favorably the difference between 1- and 5-year survival rates did not improve in Sweden suggesting that the gains in 5-year survival were entirely due to gains in 1-year survival. In Finland there was a gain in survival between years 1 and 5, but the gain in 1-years survival was the main contributor to the favorable 5-year survival. Age group specific analysis showed large survival differences, particularly among women. Towards the end of the follow-up period the differences narrowed but the disadvantage of the old patients remained in 5-year survival. The limitations of the study were lack of information on performed treatment and clinical stage in the NORDCAN database. In conclusion, the available data suggest that earlier diagnosis and surgical treatment of RCC have been the main driver of the favorable change in survival during the past 50 years. The main challenges are to reduce the age-specific survival gaps, particularly among women, and push survival gains past year 1.https://doi.org/10.1371/journal.pone.0253236
spellingShingle Kari Hemminki
Asta Försti
Akseli Hemminki
Börje Ljungberg
Otto Hemminki
Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden.
PLoS ONE
title Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden.
title_full Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden.
title_fullStr Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden.
title_full_unstemmed Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden.
title_short Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden.
title_sort progress in survival in renal cell carcinoma through 50 years evaluated in finland and sweden
url https://doi.org/10.1371/journal.pone.0253236
work_keys_str_mv AT karihemminki progressinsurvivalinrenalcellcarcinomathrough50yearsevaluatedinfinlandandsweden
AT astaforsti progressinsurvivalinrenalcellcarcinomathrough50yearsevaluatedinfinlandandsweden
AT akselihemminki progressinsurvivalinrenalcellcarcinomathrough50yearsevaluatedinfinlandandsweden
AT borjeljungberg progressinsurvivalinrenalcellcarcinomathrough50yearsevaluatedinfinlandandsweden
AT ottohemminki progressinsurvivalinrenalcellcarcinomathrough50yearsevaluatedinfinlandandsweden